Royal Bank Of Canada reaffirmed their buy rating on shares of Celgene Corporation (NASDAQ:CELG) in a research report report published on Thursday. They currently have a $173.00 target price on the biopharmaceutical company’s stock.

Other analysts also recently issued research reports about the company. BTIG Research downgraded Celgene Corporation from a buy rating to a neutral rating and raised their price target for the stock from $96.93 to $131.70 in a report on Friday, June 30th. Vetr raised Celgene Corporation from a buy rating to a strong-buy rating and set a $148.32 price target on the stock in a report on Thursday, August 10th. Morgan Stanley downgraded Celgene Corporation from an equal weight rating to an underweight rating and set a $120.00 price target on the stock. in a report on Thursday. SunTrust Banks, Inc. set a $150.00 price target on Celgene Corporation and gave the stock a buy rating in a report on Thursday, July 6th. Finally, Canaccord Genuity set a $156.00 price target on Celgene Corporation and gave the stock a buy rating in a report on Thursday, July 27th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and twenty-two have assigned a buy rating to the company’s stock. The company currently has an average rating of Buy and an average price target of $150.60.

Celgene Corporation (NASDAQ:CELG) traded down 0.57% during midday trading on Thursday, reaching $139.21. The company had a trading volume of 5,915,561 shares. The firm’s 50-day moving average price is $138.98 and its 200 day moving average price is $129.44. The firm has a market capitalization of $108.91 billion, a PE ratio of 43.11 and a beta of 1.88. Celgene Corporation has a 12 month low of $96.93 and a 12 month high of $147.17. Celgene Corporation also saw unusually large options trading on Thursday. Stock traders bought 12,607 put options on the company. This is an increase of approximately 260% compared to the typical daily volume of 3,499 put options.

Celgene Corporation (NASDAQ:CELG) last announced its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.61 by $0.21. The business had revenue of $3.27 billion for the quarter, compared to the consensus estimate of $3.23 billion. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The business’s revenue was up 18.7% on a year-over-year basis. During the same quarter last year, the business posted $1.44 EPS. Equities analysts anticipate that Celgene Corporation will post $7.32 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Celgene Corporation (CELG) Receives Buy Rating from Royal Bank Of Canada” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another site, it was illegally stolen and reposted in violation of international copyright legislation. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/10/06/celgene-corporation-celg-receives-buy-rating-from-royal-bank-of-canada.html.

In other news, Director Ernest Mario sold 18,506 shares of the firm’s stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $130.52, for a total value of $2,415,403.12. Following the completion of the sale, the director now owns 69,424 shares of the company’s stock, valued at $9,061,220.48. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Terrie Curran sold 1,727 shares of the firm’s stock in a transaction on Monday, September 25th. The stock was sold at an average price of $143.89, for a total value of $248,498.03. Following the completion of the sale, the insider now directly owns 3,925 shares of the company’s stock, valued at approximately $564,768.25. The disclosure for this sale can be found here. Insiders sold a total of 46,233 shares of company stock worth $6,268,259 over the last 90 days. Insiders own 0.95% of the company’s stock.

Several institutional investors have recently modified their holdings of CELG. Waldron LP boosted its position in shares of Celgene Corporation by 48.9% in the first quarter. Waldron LP now owns 5,207 shares of the biopharmaceutical company’s stock worth $640,000 after buying an additional 1,709 shares during the period. Security National Trust Co. boosted its position in shares of Celgene Corporation by 53.6% in the first quarter. Security National Trust Co. now owns 8,339 shares of the biopharmaceutical company’s stock worth $1,037,000 after buying an additional 2,910 shares during the period. Dowling & Yahnke LLC boosted its position in shares of Celgene Corporation by 3.5% in the first quarter. Dowling & Yahnke LLC now owns 26,917 shares of the biopharmaceutical company’s stock worth $3,349,000 after buying an additional 913 shares during the period. Jones Collombin Investment Counsel Inc boosted its position in shares of Celgene Corporation by 1,255.7% in the first quarter. Jones Collombin Investment Counsel Inc now owns 22,640 shares of the biopharmaceutical company’s stock worth $2,817,000 after buying an additional 20,970 shares during the period. Finally, Enterprise Financial Services Corp boosted its position in shares of Celgene Corporation by 622.6% in the first quarter. Enterprise Financial Services Corp now owns 2,623 shares of the biopharmaceutical company’s stock worth $326,000 after buying an additional 2,260 shares during the period. 79.36% of the stock is owned by institutional investors and hedge funds.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene Corporation (NASDAQ:CELG)

Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.